Saxonov Serge 4

What Happened

• Serge Saxonov, CEO of 10x Genomics (TXG), sold a total of 30,000 shares in open-market transactions on June 22, 2026, generating approximately $1,033,267 in proceeds.
• The sales were executed in four tranches: 8,527 shares at a weighted avg $33.29 ($283,855); 9,991 shares at $34.28 ($342,506); 9,821 shares at $35.32 ($346,837); and 1,661 shares at $36.16 ($60,069). All transactions are coded as S (sale).

Key Details

• Transaction date: June 22, 2026; Form 4 filed June 24, 2026 (filed within typical two-business-day window).
• Prices: Weighted average prices reported above; individual trades were executed in multiple fills with ranges of $32.75–$33.74, $33.76–$34.71, $34.86–$35.82, and $35.98–$36.24 (per footnotes).
• Ownership after transaction: Not provided in the supplied excerpt of the filing.
• Notable footnotes: Sales were made pursuant to a pre-established Rule 10b5-1 trading plan adopted Nov 29, 2025 (F1). Several holdings referenced in the filing are held in trusts (Andromeda Trust, Y/S Descendants' Trust, Y/S Pot Trust) for which Saxonov serves as trustee (F6–F8).
• Transaction code: S = Sale.

Context

• Sales done under a 10b5-1 plan are prearranged and generally indicate scheduled/automated selling rather than an immediate change in the insider’s view; they are common and do not necessarily signal negative sentiment.
• For retail investors, purchases by insiders often carry more informational weight than routine plan-based sales; this filing documents a routine monetization of shares rather than an acquisition.